Soleus Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Soleus Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17M	Buy	+292,000	New	+$13.5M	0.69%	39
2025 Q3	–	Sell	-78,800	Closed	-$2.47M	–	112
2025 Q2	$2.47M	Buy	+78,800	New	+$2.57M	0.16%	73
2024 Q1	–	Sell	-58,000	Closed	-$2.67M	–	101
2023 Q4	$2.67M	Buy	58,000 +6,000	+12%	+$212K	0.3%	51
2023 Q3	$1.78M	Sell	52,000 -14,000	-21%	-$524K	0.16%	70
2023 Q2	$2.54M	Buy	+66,000	New	+$2.62M	0.28%	65
2023 Q1	–	Sell	-38,000	Closed	-$1.5M	–	99
2022 Q4	$1.5M	Sell	38,000 -58,800	-61%	-$2.14M	0.22%	63
2022 Q3	$3.49M	Buy	96,800 +21,800	+29%	+$784K	0.47%	48
2022 Q2	$2.28M	Sell	75,000 -114,797	-60%	-$3.47M	0.36%	57
2022 Q1	$5.8M	Sell	189,797 -189,200	-50%	-$5.66M	0.75%	39
2021 Q4	$11.8M	Buy	378,997 +163,300	+76%	+$4.88M	1.19%	27
2021 Q3	$3.3M	Sell	215,697 -18,000	-8%	-$313K	0.51%	46
2021 Q2	$4.35M	Sell	233,697 -474,420	-67%	-$8.74M	0.67%	31
2021 Q1	$12.7M	Buy	708,117 +150,000	+27%	+$2.54M	2.28%	9
2020 Q4	$8.58M	Buy	558,117 +57,853	+12%	+$677K	1.13%	10
2020 Q3	$5.54M	Buy	500,264 +249,367	+99%	+$2.93M	2.94%	14
2020 Q2	$3.15M	Buy	250,897 +237,669	+1,797%	+$3.02M	1.79%	21
2020 Q1	$150K	Sell	13,228 -148,372	-92%	-$2.11M	0.17%	47
2019 Q4	$2.12M	Buy	+161,600	New	+$1.7M	2.04%	19

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Soleus Capital Management's XENE Position: Q1 2026 in Review

Soleus Capital Management opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 292,000 shares worth $17M. The stake represents 0.69% of the portfolio and ranks #39 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in XENE as recently as Q2 2025.

Soleus Capital Management first reported a position in XENE in Q4 2019 and has held it in 18 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Soleus Capital Management held 292,000 shares of Xenon Pharmaceuticals worth $17M as of Q1 2026.
Xenon Pharmaceuticals was a new Soleus Capital Management position in Q1 2026.
Xenon Pharmaceuticals made up 0.69% of Soleus Capital Management's portfolio in Q1 2026, its #39 holding.
Soleus Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2019 and has held it in 18 quarters since.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.